Kavitha Pharma Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
- Paid Up Capital ₹ 2.57 M
- Company Age 26 Year, 11 Months
- Last Filing with ROC 31 Mar 2021
- Open Charges ₹ 7.50 M
- Satisfied Charges ₹ 9.00 M
- Revenue Growth -75.76%
- Profit Growth 170.80%
- Ebitda -165.46%
- Net Worth 6.34%
- Total Assets -36.21%
About Kavitha Pharma
Kavitha Pharma Private Limited (KPPL) is a Private Limited Indian Non-Government Company incorporated in India on 17 March 1998 and has a history of 26 years and 11 months. Its registered office is in Chennai, Tamil Nadu, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 2.57 M.
The company currently has active open charges totaling ₹7.50 M. The company has closed loans amounting to ₹9.00 M, as per Ministry of Corporate Affairs (MCA) records.
Nagappan Gopinath and Sankaranarayanan serve as directors at the Company.
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24231TN1998PTC040128
- Company No.
040128
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Mar 1998
- Date of AGM
25 Jan 2022
- Date of Balance Sheet
31 Mar 2021
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Who are the key members and board of directors at Kavitha Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nagappan Gopinath  | Additional Director | 15-Sep-2015 | Current |
| Sankaranarayanan | Additional Director | 06-Mar-2015 | Current |
Financial Performance of Kavitha Pharma.
Kavitha Pharma Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 75.76% decrease. The company also saw a substantial improvement in profitability, with a 170.8% increase in profit. The company's net worth moved up by a moderate rise of 6.34%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Kavitha Pharma?
In 2020, Kavitha Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Yesjr Distributors Private LimitedSankaranarayanan is a mutual person
Charges (Loans)
₹7.50 M
₹9.00 M
Charges Breakdown by Lending Institutions
- City Union Bank Limited : 0.75 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 28 Sep 2016 | City Union Bank Limited | ₹7.50 M | Open |
| 31 May 1999 | Dena Bank | ₹9.00 M | Satisfied |
How Many Employees Work at Kavitha Pharma?
Unlock and access historical data on people associated with Kavitha Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Kavitha Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Kavitha Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
